

2020 年 学術報告

【発表論文】

(主に当科で行われたもの)

1. Katoh D, Ochi Y, Hiramoto N, Morita M, Yabushita T, Shimomura Y, Yamashita D, Ono Y, Yoshioka S, Yonetani N, Matsushita A, Imai Y, Hashimoto H, Ishikawa T. Parvovirus B19 infection in adult patients after allogeneic stem cell transplantation: our experience of five cases and literature review. *Bone Marrow Transplant.* 55: 653-656, 2020.
2. Shimomura Y, Hara M, Maruoka H, Yabushita T, Ishikawa T: Measurable residual disease evaluated by flow cytometry using leukemia associated immune phenotypes following allogeneic stem cell transplantation is associated with high relapse rates in patients with acute myeloid leukemia. *Leuk Lymphoma.* 61: 745-748, 2020.
3. Fujimoto A, Hiramoto N, Yamasaki S, Inamoto Y, Ogata M, Sugio Y, Fukuda T, Uchida N, Ikegame K, Matsuoka KI, Shiratori S, Kondo T, Miyamoto T, Eto T, Ichinohe T, Kanda Y, Atsuta Y, Suzuki R; Complication Working Group of the Japan Society for Hematopoietic Cell Transplantation: Low incidence of posttransplant lymphoproliferative disorder after allogeneic stem cell transplantation in patients with lymphoma treated with rituximab. *Hematol Oncol.* 38: 146-152, 2020.
4. Uchida M, Mori Y, Akiba K, Miyasaka M, Hirano T, Ikesue H, Yamaguchi Y, Takano A, Maegawa N, Shimomura Y, Hosohata K, Muroi N, Ishikawa T, Hashida T, Nakamura T: Risk Factors for Skin Toxicities Associated with Bendamustine-Based Chemotherapy in Patients with Non-Hodgkin Lymphoma. *Biol Pharm Bull.* 43: 1577-1582, 2020.
5. Inui R, Saito K, Shimomura Y, Yamashita D, Kawamoto M, Ishikawa T: Anti-Ma-associated paraneoplastic cerebellar degeneration in a patient with nodular lymphocyte-predominant Hodgkin lymphoma: a case report. *BMC Neurol.* 20: 355, 2020.
6. Kanda-Kato M, Yoshioka S, Ishikawa T: Haploidentical Hematopoietic Cell Transplantation Using Posttransplant Cyclophosphamide for Sézary Syndrome. *Case Rep Oncol.* 13: 1053-1058, 2020.
7. Nagahata Y, Kondo T, Ono Y, Hiramoto N, Kitano T, Hishizawa M, Yamashita K, Hashimoto H, Ishikawa T, Takaori-Kondo A: High-dose cytarabine chemotherapy (≥ 4 g/m²/day) before allogeneic hematopoietic stem cell transplantation for non-core-binding-factor AML in the first complete remission. *Leuk Lymphoma.* 61: 3128-3136, 2020.
8. Yoshida S, Fujimoto A, Fukushima K, Ando M, Irie K, Hirano T, Miyasaka M, Shimomura Y, Ishikawa T, Ikesue H, Muroi N, Hashida T, Sugio Y, Nishio K: Population

pharmacokinetics of tacrolimus in umbilical cord blood transplant patients focusing on the variation in red blood cell counts. *J Clin Pharm Ther.* 46: 190-197, 2021.

(共同研究)

1. Izutsu K, Minami Y, Fukuhara N, Terui Y, Jo T, Yamamoto G, Ishikawa T, Kobayashi T, Kiguchi T, Nagai H, Ohtsu T, Kalambakas S, Fustier P, Midorikawa S, Tobinai K: Analysis of Japanese patients from the AUGMENT phase III study of lenalidomide + rituximab (R2) vs. rituximab + placebo in relapsed/refractory indolent non-Hodgkin lymphoma. *Int J Hematol.* 111: 409-416, 2020.
2. Itamura H, Shindo T, Yoshioka S, Ishikawa T, Kimura S. Phosphorylated ERK1/2 in CD4 T cells is associated with acute GVHD in allogeneic hematopoietic stem cell transplantation. *Blood Adv.* 4: 667-671, 2020.
3. Matsui H, Arai Y, Imoto H, Mitsuyoshi T, Tamura N, Kondo T, Kanda J, Ishikawa T, Imada K, Ueda Y, Toda Y, Anzai N, Yago K, Nohgawa M, Yonezawa A, Tsunemine H, Itoh M, Yamamoto K, Tsuji M, Moriguchi T, Takaori-Kondo A; Kyoto Stem Cell Transplantation Group (KSCTG): Risk factors and appropriate therapeutic strategies for thrombotic microangiopathy after allogeneic HSCT. *Blood Adv.* 4: 3169-3179, 2020.
4. Kurosawa S, Shimomura Y, Tachibana T, Ishiyama K, Ota S, Kobayashi T, Uchida N, Fukushima K, Ashida T, Matsuoka KI, Kanda J, Ichinohe T, Atsuta Y, Murata M, Aoki J: Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Myelodysplastic/Myeloproliferative Neoplasms-Unclassifiable: A Retrospective Nationwide Study of the Japan Society for Hematopoietic Cell Transplantation. *Biol Blood Marrow Transplant.* 26: 1607-1611, 2020.
5. Bernard E, Nannya Y, Hasserjian RP, Devlin SM, Tuechler H, Medina-Martinez JS, Yoshizato T, Shiozawa Y, Saiki R, Malcovati L, Levine MF, Arango JE, Zhou Y, Solé F, Cargo CA, Haase D, Creignou M, Germing U, Zhang Y, Gundem G, Sarian A, van de Loosdrecht AA, Jädersten M, Tobiasson M, Kosmider O, Follo MY, Thol F, Pinheiro RF, Santini V, Kotsianidis I, Boultonwood J, Santos FPS, Schanz J, Kasahara S, Ishikawa T, Tsurumi H, Takaori-Kondo A, Kiguchi T, Polprasert C, Bennett JM, Klimek VM, Savona MR, Belickova M, Ganster C, Palomo L, Sanz G, Ades L, Della Porta MG, Smith AG, Werner Y, Patel M, Viale A, Vanness K, Neuberg DS, Stevenson KE, Menghrajani K, Bolton KL, Fenaux P, Pellagatti A, Platzbecker U, Heuser M, Valent P, Chiba S, Miyazaki Y, Finelli C, Voso MT, Shih LY, Fontenay M, Jansen JH, Cervera J, Atsuta Y, Gattermann N, Ebert BL, Bejar R, Greenberg PL, Cazzola M, Hellström-Lindberg E, Ogawa S, Papaemmanuil E: Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes. *Nat Med.* 26:

1549-1556, 2020.

6. Sekiguchi N, Rai S, Munakata W, Suzuki K, Handa H, Shibayama H, Endo T, Terui Y, Iwaki N, Fukuhara N, Tatetsu H, Iida S, Ishikawa T, Shiibashi R, Izutsu K: A multicenter, open-label, phase II study of tirabrutinib (ONO/GS-4059) in patients with Waldenström's macroglobulinemia. *Cancer Sci.* 111: 3327-3337, 2020.
7. Takezako N, Kosugi H, Matsumoto M, Iida S, Ishikawa T, Kondo Y, Ando K, Miki H, Matsumura I, Sunami K, Teshima T, Iwasaki H, Onishi Y, Kizaki M, Izutsu K, Maruyama D, Tobinai K, Ghorri R, Farooqui M, Liao J, Marinello P, Matsuda K, Koh Y, Shimamoto T, Suzuki K: Pembrolizumab plus lenalidomide and dexamethasone in treatment-naïve multiple myeloma (KEYNOTE-185): subgroup analysis in Japanese patients. *Int J Hematol.* 112: 640-649, 2020.
8. Ito A, Kim SW, Matsuoka K, Kawakita T, Tanaka T, Inamoto Y, Toubai T, Fujiwara S, Fukaya M, Kondo T, Sugita J, Nara M, Katsuoka Y, Imai Y, Nakazawa H, Kawashima I, Sakai R, Ishii A, Onizuka M, Takemura T, Terakura S, Iida H, Nakamae M, Higuchi K, Tamura S, Yoshioka S, Togitani K, Kawano N, Suzuki R, Suzumiya J, Izutsu K, Teshima T, Fukuda T: Safety and efficacy of anti-programmed cell death-1 monoclonal antibodies before and after allogeneic hematopoietic cell transplantation for relapsed or refractory Hodgkin lymphoma: a multicenter retrospective study. *Int J Hematol.* 112: 674-689, 2020.
9. Kimura SI, Fujita H, Handa H, Hiramoto N, Hosono N, Minamiguchi H, Takahashi T, Kato H, Ono T, Kanda Y, Kiyoi H, Matsumura I, Miyazaki Y; Japan Adult Leukemia Study Group (JALSG): Real-world management of infection during chemotherapy for acute leukemia in Japan: from the results of a nationwide questionnaire-based survey by the Japan Adult Leukemia Study Group. *Int J Hematol.* 112: 409-417, 2020.
10. Watanabe M, Kanda J, Arai Y, Hishizawa M, Nishikori M, Ishikawa T, Imada K, Ueda Y, Akasaka T, Yonezawa A, Nohgawa M, Kitano T, Itoh M, Takeoka T, Moriguchi T, Yago K, Arima N, Anzai N, Watanabe M, Kondo T, Takaori-Kondo A; Kyoto Stem Cell Transplantation Group (KSCTG): Impact of Donor Source on Allogeneic Hematopoietic Stem Cell Transplantation for Mature T Cell and Natural Killer Cell Neoplasms in the Kyoto Stem Cell Transplantation Group. *Biol Blood Marrow Transplant.* 26: 2346-2358, 2020.
11. Morita-Fujita M, Arai Y, Yoshioka S, Ishikawa T, Kanda J, Kondo T, Akasaka T, Ueda Y, Imada K, Moriguchi T, Yago K, Kitano T, Yonezawa A, Nohgawa M, Takaori-Kondo A; Kyoto Stem Cell Transplantation Group (KSCTG): Indication and benefit of upfront hematopoietic stem cell transplantation for T-cell lymphoblastic lymphoma in the era of ALL-type induction therapies. *Sci Rep.* 10: 21418, 2020.

12. Sugita J, Kamimura T, Ishikawa T, Ota S, Eto T, Kuroha T, Miyazaki Y, Kumagai H, Matsuo K, Akashi K, Taniguchi S, Harada M, Teshima T: Reduced dose of posttransplant cyclophosphamide in HLA-haploidentical peripheral blood stem cell transplantation. *Bone Marrow Transplant.* 56: 596-604, 2021.
13. Izutsu K, Yamamoto K, Kato K, Ishikawa T, Fukuhara N, Terui Y, Choi I, Humphrey K, Kim SY, Okubo S, Ogawa N, Nishimura Y, Salem AH, Maruyama D: Phase 1/2 study of venetoclax, a BCL-2 inhibitor, in Japanese patients with relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma. *Int J Hematol.* 113: 370-380, 2021.

【学会発表】

1. 米谷昇 G-Benda 治療後早期に形質転換をきたした FL の 2 例 Hematology Conference in Osaka 大阪 2020.2.7
2. 森拓人、平本展大、上田亮介、下村良充、吉岡聡、石川隆之 臍帯血移植において CY/TBI 前処置と Tac/MMF GVHD 予防は HHV-6 脳炎のリスク因子である 第 42 回日本造血細胞移植学会総会 東京 2020.3.6
3. 井本寛東、平本展大、上條公守、岡田直樹、斎藤健貴、森拓人、神田まどか、下村良充、上田亮介、吉岡聡、米谷昇、松下章子、石川隆之 当院における EBV 関連 T/NK 細胞リンパ増殖性疾患に対する同種造血幹細胞移植の治療成績 第 42 回日本造血細胞移植学会総会 東京 2020.3.7
4. 上條公守、下村良充、岡田直樹、斎藤健貴、井本寛東、神田まどか、森拓人、上田亮介、平本展大、吉岡聡、米谷昇、松下章子、石川隆之 血液腫瘍患者における PTCY を用いた HLA 半合致移植の単一施設における後方視的検討 第 42 回日本造血細胞移植学会総会 東京 2020.3.7
5. 下村良充、原正彦、平林茂樹、近藤忠一、水野昌平、内田直之、河北敏郎、土岐典子、福田隆浩、和氣敦、神田善伸、木村貴文、一戸辰夫、熱田由子、柳田正光 非寛解急性白血病における Flu/Bu4/Mel と従来型骨髄破壊的前処置の比較 第 42 回日本造血細胞移植学会総会（プレナリー）東京 2020.3.7
6. 三木隼、上條公守、吉岡聡、石川隆之、清水祐里、原 重雄：急速に進行する腎機能障害で発症し、腎生検が診断の一助となった形質細胞腫瘍の 1 例. 第 229 回日本内科学会近畿地方会、大阪、2020.9.26
7. Takeda J, Yoshida K, Yoda A, Nannya Y, Shih L, Ochi Y, Shiraishi Y, Kerr C, Nagata Y, Kitano T, Hangaishi A, Ishiyama K, Tsurumi H, Miyazaki Y, Hiramoto N, Ishikawa T, Nakagawa M, Takaori A, Chiba S, Nakazawa H, Kuo M, Kataoka K, Saiki R, Sanada M, Usuki K, Miyawaki S, Miyano S, Maciejewski J, Makishima H, Ogawa S: JAK/STAT pathway is a promising therapeutic target in acute erythroid leukemia. 第 82 回日

本血液学会総会、京都、2020.10.9

8. Nannya Y, Makishima H, Takeda J, Momozawa Y, Saiki R, Yoshizato T, Miyazaki Y, Ishikawa T, Tsurumi H, Kasahara S, Takaori A, Ohyashiki K, Kiguchi T, Matsuda F, Jaroswal M, Eva L, Chantana P, Mario C, Torsten H, Kamatani Y, Kubo M, Miyano S, Ogawa S: The role of germline and somatic DDX41 mutations on myeloid malignancies. 第 82 回日本血液学会総会、京都、2020.10.9
9. Maeda T, Matsuda A, Kanda J, Kawabata H, Ishikawa I, Tohyama K, Araseki K, Shimbo K, Hata T, Suzuki T, Kayano H, Usuki K, Shindo M, Arima N, Nohgawa M, Ohta A, Chiba S, Miyazaki Y, Nakao S, Ozawa K, Arai S, Kurokawa M, Takaori A, Mitani K: Impact of the dysplastic signs on prognosis for patients with FAB-RA except 5q- syndrome 第 82 回日本血液学会総会、京都、2020.10.9
10. Sekiguchi N, Teshima T, Ishizawa K, Ando K, Shimada K, Ishikawa T, Maeda Y, Matsumoto M, Aotsuka N, Terui Y, Zhu Y, Nahar A, Marinello P, Yamamoto Y, Shimamoto T, Kuruvilla J, Matsumura I: KEYNOTE-204: phase 3 study of pembrolizumab vs brentuximab vedotin in R/R classical Hodgkin lymphoma 第 82 回日本血液学会総会、京都、2020.10.9.
11. Yamamoto K, Ando K, Maruyama D, Kiyohara E, Terui Y, Fukuhara N, Miyagaki T, Kawai H, Tokura Y, Sakata-Yanagimoto M, Igarashi T, Kuroda J, Fujita J, Uchida T, Ishikawa T, Yonekura K, Kato K, Nakanishi T, Nakai K, Matsunaga R, Tobinai K: Phase 2 study of E7777 on relapsed or refractory, peripheral and cutaneous T-cell lymphoma in Japan 第 82 回日本血液学会総会、京都、2020.10.9.
12. Rai S, Sekiguchi N, Munakata W, Suzuki K, Handa H, Shibayama H, Endo T, Terui Y, Iwaki N, Fukuhara N, Tatetsu H, Iida S, Ishikawa T, Iguchi D, Izutsu K: Phase II study of tirabrutinib in Japanese patients with Waldenstrom's macroglobulinemia 第 82 回日本血液学会総会、京都、2020.10.9.
13. Shibayama H, Rai S, Izutsu K, Yamaguchi M, Takizawa J, Kuroda J, Ishikawa T, Kato K, Suehiro Y, Fukuhara N, Ohmine K, Goto H, Yamamoto K, Kanemura N, Ueda Y, Ishizawa K, Kumagai K, Kawasaki A, Saito T, Hashizume M, Terui Y: Polatuzumab vedotin with bendamustine and rituximab in r/r DLBCL (P-DRIVE): A phase 2 study in Japan 第 82 回日本血液学会総会、京都、2020.10.9.
14. Nishikubo M, Imoto H, Hiramoto N, Ishikawa T, Yamashita D, Sato Y, Kimura H: Elderly-onset systemic EBV-positive T-cell lymphoproliferative diseases of childhood 第 82 回日本血液学会総会、京都、2020.10.9.
15. Takamatsu H, Fujisaki T, Ishikawa T, Suzuki K, Min CK, Lee JH, Wang J, Kudva A, Kobos R, Wroblewski S, Nagafuji K: Daratumumab plus VMP (D-VMP) in non-transplant NDMM: updated results of Asian subgroups (alcyone) 第 82 回日本血液

学会総会、京都、2020.10.9.

16. Iida S, Ishikawa T, Min CK, Kim KH, Yeh SP, Usmani SZ, Mateos MV, Nahi H, Heuck C, Qin X, Parasrampur DA, Gries KS, Qi M, Lantz K, Masterson T, Bahlis NJ, Ito S: Daratumumab subcutaneous (DARA SC) administration in Asian pts with RRMM: Update of COLUMBA 第 82 回日本血液学会総会、京都、2020.10.9.
17. Yamashita D, Hiramoto N, Sakamoto K, Takeuchi K, Nagano T, Ishikawa T, Hara S: Blastic plasmacytoid dendritic cell neoplasm: A clinicopathological analysis of 5 cases 第 82 回日本血液学会総会、京都、2020.10.9.
18. Imoto H, Hiramoto N, Mori T, Yamashita D, Nannya Y, Ogawa S, Ishikawa T: Myelodysplastic syndrome arising from JAK2-unmutated clones in essential thrombocythemia 第 82 回日本血液学会総会、京都、2020.10.9.
19. Yamada C, Shimomura Y, Kamijyo K, Kanda M, Yoshioka S, Yonetani N, Ishikawa T: A case of BCR-ABL1-positive B-lymphoblastic lymphoma 第 82 回日本血液学会総会、京都、2020.10.9.
20. 西久保雅司 新型コロナウイルス感染症禍における血液疾患患者の感染対策 -第 1 波における院内感染の経験を踏まえて- 血液疾患ライブ配信講演会 in 兵庫 2020.11.14